About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Hemophilia Inhibitor Previously Untreated Patient Study

NCT01652027·17 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

The University of Texas Health Science Center, Houston

With

Rho, Inc.
Baxter Healthcare Corporation

Age

Any age

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Severe hemophilia A with FVIII activity \< 1% normal
Weight \> 3.5 kg at the time of baseline study evaluation
Informed consent, approved by appropriate Institutional Review Board/Independent Ethics Committee, has been administered, signed, and dated

You may not be if

Prior exposure to clotting factor concentrates or blood products
Other chronic disease
Currently participating in another investigational drug study.

The record

StatusCompleted

PhaseNo phase

Taking part25

StartedJul 2011

UpdatedNov 10, 2020

Conditions

Where17

Emory University
Atlanta, Georgia, United States
Indiana Hemophilia and Thrombosis Center
Indianapolis, Indiana, United States
University of Kentucky
Lexington, Kentucky, United States

Clareo Health | Hemophilia Inhibitor Previously Untreated Patient Study